Among patients who persisted with their medication one year after their initial prescriptions, the proportion who achieved 10% or more weight reduction was 61% with semaglutide for obesity, 23.1% with semaglutide for type 2 diabetes, 28.6% with liraglutide for obesity, and 12.3% with liraglutide for type 2 diabetes
A provider finishes a weight loss follow-up visit, adjusts a patients semaglutide dose, orders labs, sends a refill to the pharmacy, and documents the visit
Dermatol 12, 881885
What to track when Not everything needs to be logged with the same frequency
Semaglutide has approvals for reducing cardiovascular risks in patients with heart disease, protecting kidney function in those with chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
Ya ests suscrito a este producto